ReviewImmunotherapy advances2021
A glutamine 'tug-of-war': targets to manipulate glutamine metabolism for cancer immunotherapy.
Review in Immunotherapy advances, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Chronic Ammonia Stress in Chinese Perch (Antioxidants (Basel, Switzerland) · 2025Article
- Metabolic reprogramming and immunological changes in the microenvironment of esophageal cancer: future directions and prospects.Frontiers in immunology · 2025Review
- Immunotherapy resistance in solid tumors: mechanisms and potential solutions.Cancer biology & therapy · 2024Review
- Review
- A glutamine tug-of-war between cancer and immune cells: recent advances in unraveling the ongoing battle.Journal of experimental & clinical cancer research : CR · 2024Review
- Glutamine Supplementation as an Anticancer Strategy: A Potential Therapeutic Alternative to the Convention.Cancers · 2024Review
- Dietary Manipulation of Amino Acids for Cancer Therapy.Nutrients · 2023Review
- Targeting Cancer Metabolism to Improve Outcomes with Immune Checkpoint Inhibitors.Journal of immunotherapy and precision oncology · 2023Review
- Glutamine metabolic reprogramming in hepatocellular carcinoma.Frontiers in molecular biosciences · 2023Review
- Circ_0001093 promotes glutamine metabolism and cancer progression of esophageal squamous cell carcinoma by targeting miR-579-3p/glutaminase axis.Journal of bioenergetics and biomembranes · 2022Article
- Combining PEGylated mito-atovaquone with MCT and Krebs cycle redox inhibitors as a potential strategy to abrogate tumor cell proliferation.Scientific reports · 2022Article
- Review
- Partners in crime: The feedback loop between metabolic reprogramming and immune checkpoints in the tumor microenvironment.Frontiers in oncology · 2022Review
- Immunometabolism - The Role of Branched-Chain Amino Acids.Frontiers in immunology · 2022Review
- Immunotherapy advances: One year on.Immunotherapy advances · 2022Article
- α-Ketoglutaramate-A key metabolite contributing to glutamine addiction in cancer cells.Frontiers in medicine · 2022Article
- Harnessing immunometabolism for cardiovascular health and cancer therapy.Immunotherapy advances · 2021Article
Corrections and comments
- Erratum issuedCorrection.2022
Authors and funding
5 authors.
Funding
Abstract
Within the tumour microenvironment (TME), there is a cellular 'tug-of-war' for glutamine, the most abundant amino acid in the body. This competition is most evident when considering the balance between a successful anti-tumour immune response and the uncontrolled growth of tumour cells that are addicted to glutamine. The differential effects of manipulating glutamine abundance in individual cell types is an area of intense research and debate. Here, we discuss some of the current strategies in development altering local glutamine availability focusing on inhibition of enzymes involved in the utilisation of glutamine and its uptake by cells in the TME. Further studies are urgently needed to complete our understanding of glutamine metabolism, to provide critical insights into the pathways that represent promising targets and for the development of novel therapeutic strategies for the treatment of advanced or drug resistant cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.